Busulphan
Niemann-Pick Disease Type B
Masonic Cancer Center, University of MinnesotaPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Niemann-Pick Disease Type B cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cald Hr-D Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Campath-1H Masonic Cancer Center, University of Minnesota | Phase 2 | CC |
Same molecule, other indications
Busulphan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →